

## Pembrolizumab (HL)

### Indication

Treatment of relapsed or refractory classical Hodgkin Lymphoma in patients who have had at least 2 previous treatments including brentuximab vedotin and who cannot have autologous stem cell transplant.

(NICE TA967)

Treatment of relapsed or refractory classical Hodgkin lymphoma in patients previously treated with a stem cell transplant but who have not previously received brentuximab vedotin

(NICE TA772)

### ICD-10 codes

Codes prefixed with C81.

### Regimen details

**Three weekly regimen:**

Day	Drug	Dose	Route
1	Pembrolizumab	200mg	IV infusion

or

**Six weekly regimen:**

Day	Drug	Dose	Route
1	Pembrolizumab	400mg	IV infusion

### Cycle frequency

21 days (200mg dose)

or

42 days (400mg dose)

### Number of cycles

Until unacceptable toxicity, disease progression, stem cell transplant or to a maximum of 2 years.

### Administration

Pembrolizumab should be administered in 100mL sodium chloride 0.9% over 30 minutes.

Pembrolizumab should be administered via an infusion set with an in-line sterile, non-pyrogenic, low protein binding filter (pore size 0.2 – 5.0µm).

After the infusion the line should be flushed with 30mL sodium chloride 0.9%.

Patients should be monitored every 30 minutes during the infusion (blood pressure, pulse and temperature) and for infusion related reactions. For mild to moderate reactions, decrease the infusion rate and closely monitor. Premedication with paracetamol and chlorphenamine should be used for further doses. For severe infusion related reactions discontinue treatment.

### Pre-medication

Nil

### Emetogenicity

This regimen has low emetogenic potential

### Additional supportive medication

Loperamide should be supplied to be used if required.

Antiemetics as per local policy, if required.

### Extravasation

Neutral (Group 1)

### Investigations – pre first cycle

Investigation	Validity period (or as per local policy)
FBC	14 days
U+E (including creatinine)	14 days
LFT	14 days
Thyroid function	14 days
Glucose	14 days
Calcium	14 days
Cortisol	At consultant discretion

Other baseline investigations:

Hepatitis B core antibody and hepatitis BsAg, hepatitis C antibody, EBV, CNV. VZV, HIV 1+2.

### Investigations – pre subsequent cycles

Investigation	Validity period (or as per local policy)
FBC	7 days
U+E (including creatinine)	7 days
LFT	7 days
Thyroid function	6 weekly
Glucose	As clinically indicated
Calcium	As clinically indicated
Cortisol	At consultant discretion

### Standard limits for administration to go ahead

If blood results not within range, authorisation to administer **must** be given by prescriber/ consultant.

Investigation	Limit
Neutrophil count	$\geq 1.0 \times 10^9/L$
Platelets	$\geq 75 \times 10^9/L$
Creatinine Clearance (CrCl)	$\geq 30\text{mL}/\text{min}$
Bilirubin	$\leq 1.5 \times \text{ULN}$
ALT/AST	$< 3 \times \text{ULN}$
Alkaline Phosphatase	$< 5 \times \text{ULN}$

### Dose modifications

- **Haematological toxicity**

Discuss with the consultant if:

Neutrophils  $< 1.0 \times 10^9/L$

Platelets  $< 75 \times 10^9/L$

- **Renal impairment**

The safety and efficacy of pembrolizumab has not been studied in patients with renal impairment. No specific dose adjustments are recommended in mild to moderate renal impairment.

Discuss with consultant if CrCl <30mL/min.

- **Hepatic impairment**

The safety and efficacy of pembrolizumab has not been studied in patients with hepatic impairment. No specific dose adjustments are recommended in mild hepatic impairment. See below for management of hepatitis.

- **Other toxicities**

Patients must be advised to seek specialist advice if they experience side effects as these can worsen rapidly. Immune reactions may occur during or after completion of treatment.

Toxicity	Definition	Action
Colitis	Grade 1	Continue and closely monitor
	Grade 2-3	Withhold until symptoms resolve to ≤ grade 1
	Grade 4	Permanently discontinue pembrolizumab
Pneumonitis	Grade 1	Continue and closely monitor
	Grade 2	Withhold until symptoms resolve to ≤ grade 1
	Grade 3-4 or recurrent grade 2	Permanently discontinue pembrolizumab
Nephritis	Grade 2 (creatinine 1.5-3 x ULN)	Withhold until symptoms resolve to ≤ grade 1
	Grade 3 (creatinine > 3 x ULN)	Permanently discontinue pembrolizumab
Endocrine	Symptomatic hypophysitis	Withhold until symptoms resolve to ≤ grade 1
	Type 1 diabetes with grade > 3 hyperglycaemia (glucose > 13.9 mmol/L) or ketoacidosis	Withhold until ≤ grade 2 May consider recommencing after corticosteroid taper or discontinue.
	Hyperthyroidism ≥ grade 3	Withhold until ≤ grade 2 May consider recommencing after corticosteroid taper or discontinue.
	Hypothyroidism	Continue and manage with replacement therapy
Hepatitis	AST/ALT 3-5 x ULN or Bilirubin > 1.5-3 x ULN	Withhold until resolves to ≤ grade 1
	AST/ALT > 5 x ULN or Bilirubin > 3 x ULN	Permanently discontinue pembrolizumab
	If liver metastasis with baseline AST/ALT 3-5 x ULN: - If AST/ALT increases ≥ 50% for ≥ 1 week	Permanently discontinue pembrolizumab
Skin reactions	Grade 3 or suspected Stevens-Johnson syndrome or toxic epidermal necrolysis	Withhold until resolves to ≤ grade 1
	Grade 4 or confirmed Stevens-Johnson syndrome or toxic epidermal necrolysis	Permanently discontinue pembrolizumab
Infusion-related reactions	Grade 3-4	Permanently discontinue pembrolizumab

Pembrolizumab should be permanently discontinued if:

- Grade 4 toxicity (except for endocrinopathies that are controlled with replacement hormones)
- Corticosteroid dosing cannot be reduced to ≤10 mg prednisone or equivalent per day within 12 weeks
- Treatment-related toxicity does not resolve to Grade 0-1 within 12 weeks after last dose
- Any event occurs a second time at Grade ≥ 3 severity
- Grade 3 or 4 myocarditis
- Grade 3 or 4 encephalitis
- Grade 3 or 4 Guillain-Barré syndrome

**Adverse effects** - for full details consult product literature/ reference texts**• Serious side effects**

Myelosuppression  
Pneumonitis  
Colitis  
Hepatitis  
Nephritis  
Endocrinopathies  
Pancreatitis  
Myocarditis  
Encephalitis

**• Frequently occurring side effects**

Myelosuppression  
Reduced appetite  
Headache  
Dizziness  
Dry eyes  
Cough  
Diarrhoea  
Nausea  
Rash, pruritis  
Fatigue  
Hyperglycaemia  
Hypocalcaemia  
Hyperthyroidism, hypothyroidism

**• Other side effects**

Arthralgia

**Significant drug interactions** – for full details consult product literature/ reference texts

**Corticosteroids:** use of systemic corticosteroids at baseline, before starting pembrolizumab, should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of pembrolizumab. However, systemic corticosteroids or other immunosuppressants can be used after starting pembrolizumab to treat immune-related adverse reactions.

**Additional comments**

Women of child bearing potential should use effective contraception during treatment and for at least 4 months after the last dose.

Preliminary results from the follow-up of patients undergoing allogeneic HSCT after previous exposure to pembrolizumab showed a higher than expected number of cases of acute graft versus-host-disease (aGVHD) and transplant related mortality (TRM). Until further data become available, careful consideration to the potential benefits of HSCT and the possible increased risk of transplant related complications should be made case by case. Solid organ transplant rejection has been reported in the post-marketing setting in patients treated with PD-1 inhibitors.

---

**References**

- National Institute for Health and Clinical Excellence TA967 accessed 02 May 2024 via [www.nice.org.uk](http://www.nice.org.uk)
- National Institute for Health and Clinical Excellence TA772 accessed 29 June 2022 via [www.nice.org.uk](http://www.nice.org.uk)
- Summary of Product Characteristics Pembrolizumab - Keytruda® (MSD) accessed 10 July 2019 via [www.medicines.org.uk](http://www.medicines.org.uk)
- Chen, R, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017 Jul 1;35(19):2125-2132
- Kuruville, J. et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021 22(4):512-524

---

Written/reviewed by: Dr S Otton (Consultant Haematologist, North Bristol NHS Trust)

Checked by: Sarah Murdoch (Senior Oncology/Haematology Pharmacist, SW Clinical Network), Kate Gregory (lead Pharmacist for SACT protocols, SWAG Cancer Alliance)

Authorised by: Dr J Braybrooke (Consultant Oncologist, SW Clinical Network)

Date: July 2019

---